- Published at
- by manilatimes.net
positive
positive
News for Shanghai Junshi Biosciences Co., Ltd. (688180.SS)
- Published at
- by financialpost.com
positivepositiveJunshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe
SHANGHAI, Jan. 20, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biophar…- Published at
- by manilatimes.net
positivepositive- Published at
- by financialpost.com
positivepositiveJunshi Biosciences Announces Toripalimab's Approval in Australia
SHANGHAI, Jan. 17, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biophar…- Published at
- by gurufocus.com
mixedmixedDr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as ”Dr. Reddy's”),- Published at
- by investing.com
mixedmixedDr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma By Investing.com
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma- Published at
- by thehindubusinessline.com
positivepositiveDr Reddy’s launches nasopharyngeal carcinoma drug Toripalimab in India
Dr. Reddy's launches Toripalimab, a new cancer treatment for nasopharyngeal carcinoma, addressing unmet needs in India.- Published at
- by financialpost.com
positivepositiveJunshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biophar…- Published at
- by manilatimes.net
positivepositive- Published at
- by globenewswire.com
mixedmixedImmune Checkpoint Inhibitors Market to hit USD 189.1 billion by 2032, says Global Market Insights Inc.
Immune checkpoint inhibitors industry is projected to witness a CAGR of 16.7% during the period 2024-2032. This growth can be attributed to ongoing...- Published at
- by investing.com
positivepositiveJunshi Biosciences Announces European Commission Approval for Marketing of Toripalimab By Investing.com
Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab- Published at
- by investing.com
positivepositiveJunshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates By Investing.com
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates- Published at
- by investing.com
positivepositive- Published at
- by seekingalpha.com
mixedmixedRevolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD)
Revolution is pioneering a unique precision-based approach to developing oncology drugs that target the RAS pathway. Read why I'm neutral on RVMD stock.- Published at
- by marketscreener.com
mixedmixedCoherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Ca
– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC...- Published at
- by globenewswire.com
mixedmixedCoherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
– LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy...- Published at
- by globenewswire.com
mixedmixedCoherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status...- Published at
- by globenewswire.com
mixedmixedNasopharyngeal Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 28+ Companies Working in the Domain
The prevalence of Nasopharyngeal Cancer is increasing globally due to environmental, pathogen-mediated, and genetic factors as well as lifestyle factors,...- Published at
- by prnewswire.com
mixedmixedGlobal COVID-19 Therapeutics Market worth $14.6 billion by 2022 - Exclusive Report by InsightAce Analytic
/PRNewswire/ -- The newly published report titled "Global COVID-19 Therapeutics Market– By Trends, Industry Competition Analysis, Clinical Trial/Pipeline...- Published at
- by investing.com
mixedmixedDrugmakers cut prices by 62% on average to get China state insurance listing By Reuters
Drugmakers cut prices by 62% on average to get China state insurance listing